The table below shows Tarsus Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$24.65M
-$20.65M
-$37.79M
-$21.97M
-$15.29M
-$11.79M
Capital expenditure
$5.82M
$590.00K
$174.00K
$340.00K
$161.00K
$175.00K
Investing cash flow
-$58.56M
-$34.94M
-$102.22M
$11.29M
-$161.00K
-$175.00K
Dividends paid
-
-
-
TARS operating cash flow (10-K history)
Tarsus Pharmaceuticals, Inc. reported operating cash flow of -$12.45M for fiscal year 2025. That is up 85.0% from -$83.03M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$3.67M (FY 2019) to -$12.45M. Figures come from the company's audited annual reports as filed with the SEC.